NIFTY 50

IPO of biologics division likely in next few years, says Biocon's Kiran Mazumdar Shaw

Updated : May 15, 2019 11:13 AM IST

Annualised numbers for biologics segment have almost doubled YoY: Biocon
Don't find it reasonable the way biologics business is being looked at: Biocon
Delivered strong growth in biosimilar segment in emerging markets: Biocon
primo org
Have you signed up for Primo, our daily newsletter?
It has all the stories and data on the market, business, economy and tech that you need to know.
cnbc two logos
To keep watching CNBC-TV18, India's No. 1 English Business News Channel, call your Cable or DTH Operator and subscribe now for just Rs. 4 per month. You can also subscribe to CNBC-TV18 Prime HD for Re 1/- per month.Find out more

You May Also Like

Live TV